Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $22.60 Average Target Price from Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $22.60.

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus reissued a “hold” rating and issued a $6.00 price objective (down from $24.00) on shares of Aardvark Therapeutics in a research report on Monday, March 2nd. Royal Bank Of Canada cut Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $18.00 to $6.00 in a research report on Monday, March 2nd. Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 price objective on shares of Aardvark Therapeutics in a research report on Monday, January 12th. Oppenheimer reduced their price objective on Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Finally, B. Riley Financial assumed coverage on Aardvark Therapeutics in a research report on Wednesday, January 28th. They issued a “buy” rating and a $32.00 price objective for the company.

Aardvark Therapeutics Stock Down 2.2%

Shares of Aardvark Therapeutics stock opened at $4.04 on Wednesday. The stock has a market capitalization of $88.15 million, a P/E ratio of -1.38 and a beta of 5.33. The stock has a 50 day moving average price of $8.33 and a two-hundred day moving average price of $11.30. Aardvark Therapeutics has a 12-month low of $3.35 and a 12-month high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last announced its earnings results on Monday, March 23rd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.81).

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Aardvark Therapeutics in the second quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aardvark Therapeutics in the fourth quarter valued at approximately $47,000. Persistent Asset Partners Ltd bought a new position in Aardvark Therapeutics in the fourth quarter worth $56,000. New York State Common Retirement Fund bought a new position in Aardvark Therapeutics in the second quarter worth $99,000. Finally, MetLife Investment Management LLC bought a new position in Aardvark Therapeutics in the fourth quarter worth $102,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.